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Background: Bladder cancer (BC) is among the most common malignancies worldwide. The identification of new biomarkers for
early BC detection, recurrence/progression is urgently needed. The cytokinesis-block micronucleus assay (CBMN) evaluates
chromosome damage in cultured human lymphocytes and micronuclei (MN) provide a convenient and reliable index of both
chromosome breakage and loss.
Methods: Chromosomal damage (expressed as frequencies of MN, nucleoplasmic bridges and nuclear buds (NBUD)) was
evaluated by CBMN assay in cryopreserved lymphocytes from 158 age/smoking-matched pairs of cases and controls in relation to
BC risk, recurrence or progression. Moreover, non-muscle invasive BC (NMIBC) patients were characterised for 783 DNA repair
gene polymorphisms for their possible association with the investigated cytogenetic end points.
Results: MN and NBUD frequencies were significantly higher in cases than in controls (P¼ 0.001 and P¼ 0.006, respectively), with
the associations being stronger in NMIBC. In a logistic regression model, for each increase of one unit in the MN frequency, a 1.12
increased risk of developing NMIBC was observed. In NMIBC cases, 10 polymorphisms were associated with different MN
frequencies after genotype stratification.
Conclusions: A model including traditional BC risk factors, MN frequency and the selected polymorphisms differentially distributed in
cases and controls improved BC patient identification. Understanding the meaning of systemic chromosomal damage in BC patients
with respect to the general population may help to adopt specific prevention strategies and therapeutic intervention.
Bladder cancer (BC) is the fifth most common malignancy in the
general population and its incidence increases with age, which
represents the most significant risk factor for it. Men are
predominantly affected, with a 3 : 1 male:female ratio (Ferlay
et al, 2015). A wide range of environmental risk factors has been
identified among which are tobacco smoking, consumption of
arsenic-contaminated water, occupational exposure to aromatic
amines and polycyclic hydrocarbons, and chronic infection with
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Schistosoma species (Matullo et al, 2015). Several germline
variants have also been recognised as contributors to BC risk
(Dudek et al, 2013).
At diagnosis, the majority of BC are non-muscle invasive (80%,
Stage Ta-T1; NMIBC) and only 20% of all diagnosed BC cases are
muscle-invasive (Stage T2 and above; MIBC). Despite endovesical
treatment, NMIBCs frequently recur (50–70%) and sometimes
progress to detrusor muscle invasion (10–15%; Sylvester et al,
2006). Cystoscopy is the most used way to monitor these patients
who frequently undergo multiple endoscopic resections over the
years. Risk tables provide a prognostic tool regarding the risk of
recurrence and progression of NMIBC, whereas the prognosis of
MIBC patients is less favourable due to a high risk of metastatic
progression, independently of treatment. Up-to-date, there are no
molecular biomarkers to accurately predict disease progression
(Soloway, 2013).
As for many other cancers, also for BC there is an established
variation of individual susceptibility that may be modulated by
interaction of environmental exposures and genetic factors.
Biologic variability may occur at any stage of carcinogenesis;
therefore, variation in inter-individual susceptibility poses a
challenge in quantitative human risk assessment and warrants
testing and validation of biomarkers that allow accurate identifica-
tion of high-risk individuals. Evidence that cytogenetic biomarkers
are positively correlated with cancer risk has been strongly
validated in both cohort and nested case-control studies, leading
to the conclusion that chromosome aberrations are a relevant
marker of cancer risk (Bonassi et al, 2004), which reflects the
outcome of both the genotoxic effects of carcinogens and the
genetic host susceptibility. The cytokinesis-block micronucleus
(CBMN) assay is a relatively fast and easy technique extensively
used in molecular epidemiology and cytogenetics. The assay is
applied to evaluate the presence and the extent of chromosomal
damage in populations exposed to genotoxic agents or in case of
the presence of a susceptible genetic profile in several cell types,
including newly divided peripheral blood mononuclear cells
(PBMC; Bonassi et al, 2007). The measurement of micronucleus
(MN) frequency in PBMC has also been applied for the
identification of dietary and genetic factors with a significant
impact on genome stability. The high reliability and low cost of the
CBMN technique has contributed to its success worldwide and to
the adoption for in vitro and in vivo studies of genome damage
(Bonassi et al, 2007). Similarly to other in vitro cytogenetic assays,
there is a known inter- and intra-laboratory variability. However,
there are still limited information on the effects of the laboratory
method, subject lifestyle and the role of individual susceptibility on
this variability. The long-term health significance of PBMC MN is
also a major issue to be clarified. The International Human
Micronucleus (HUMN) Project (www.humn.org) was created in this
sense to coordinate worldwide research efforts aimed at using CBMN
assays to study DNA damage in human populations and to establish
standardised protocols so that data comparisons can be made more
reliably across laboratories and countries (Fenech et al, 2011a).
The origin of MN is from whole chromosomes not included in
the main daughter nuclei or from chromosome fragments that
are lost during nuclear division. In dividing cells, the formation
of MN derives from chromosome malsegregation due to mitotic
malfunction or from unrepaired/misrepaired DNA lesions that
generate chromosome breakage. The events described may be
induced by several factors including oxidative stress, exposure
to clastogens or aneugens, various genetic defects involving
malfunctions of the cell cycle checkpoints and/or DNA repair, as
well as deficiencies of nutrients important as cofactors for the
metabolism of DNA and for the machinery of chromosome
segregation (Fenech, 2007). Therefore, the CBMN assay can be
considered a possible test to evaluate the level of DNA damage in
the cells.
In the present study, we evaluated whether MN frequency as
detected by the CBMN assay can be used as a potential molecular
biomarker to identify individuals with increased risk of BC,
recurrence or progression in a large hospital-based case-control
study (158 cases and 158 controls matched for gender (all males),
age and smoking habits). The assay was performed on cryopre-
served PBMC. Additionally, the distribution of genotypes of a large
number of polymorphisms in DNA repair genes among cases
(NMIBC) and controls and their associations with the frequencies
of the analysed CBMN end points were investigated.
MATERIALS AND METHODS
Study population. The study population included newly diag-
nosed, histologically confirmed cases of BC included in the Turin
Bladder Cancer Study (Sacerdote et al, 2013; Russo et al, 2014).
Controls were men recruited during the same period as cases in
random fashion from patients treated at the same urology
departments for non-neoplastic disease or from patients treated
at the medical and surgical departments for various problems
(hernias, vasculopathies, diabetes, heart failure, asthma or other
benign diseases). Detailed description of the study population is
given in the Supplementary Materials and Methods. All subjects
were informed and provided written informed consent according
to the Helsinki declaration. The design of the study was approved
by the local Ethics Committees.
Isolation and storing of lymphocytes. The isolation and storing
of lymphocytes was described in Turinetto et al (2016). A more
detailed description of the process is given in the Supplementary
Materials and Methods.
Cytokinesis-block micronucleus assay. Cryopreserved PBMC
from 158 cases (collected before treatment) and 158 controls
matched by age (±1 year) and smoking habits, were selected from
the Turin Bladder Cancer Study collection and processed for the
CBMN assay.
Cell lymphocytes cultures were set up according to Zijno et al
(2007). A detailed description of the assay is given in the
Supplementary Materials and Methods. For each blood sample at
least two cultures were set up in round-bottomed tissue cultures
tubes. For each experiment 7–8 samples were processed.
For each subject, 1000 binucleated cells were scored from
untreated cultures (500 cells from each of two cultures). Scoring of
binucleated cells with MN, nucleoplasmic bridges (NPB) and
nuclear buds (NBUD) was performed by two independent scorers
following the criteria developed by Fenech et al (2007). Cell
proliferation was evaluated determining the nuclear division index
in 500 cells. Nuclear division index was calculated as follows:
(M1þ 2M2þ 3M3þ 4M4)/N, where M1–M4 represent the num-
ber of cells with 1–4 nuclei respectively, and N is the total number
of viable cells scored.
Genotyping and quality controls. DNA was isolated from PBMC
with the Qiagen DNeasy blood and tissue kit (Qiagen, Milan, Italy)
according to the manufacturer’s protocol.
Whole-genome genotyping was performed on an Illumina
HumanOmniExpressExome-8 v1.2 (containing 964193 single
nucleotide polymorphisms (SNPs)) for 306 subjects. Genotypes
were assessed by GenomeStudio V2011.1 (Illumina, San Diego,
CA, USA).
A cut-off for a genotyping call rate of 0.90 was set, leading to the
exclusion of three study subjects. The identity by descent
estimation was used to check relatedness among subjects (R
3.0.3, SNPRelate package). Subjects with kinship coefficient
40.0625 (two couples) were considered consanguineous and
excluded (one per couple) from further analyses. Population
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structure was investigated through Principal Component Analysis:
two outlier subjects were found and then removed, leaving 299
subjects (152 cases and 147 controls).
SNPs having 45% missing genotypes (n¼ 7854), deviating
from Hardy–Weinberg equilibrium (Po0.0001, n¼ 378) or with
minor allele frequencyo5% (n¼ 339,031) were excluded from the
analysis, for a final study data set of 616454 SNPs. From 5412 SNPs
in DNA repair genes present in the Illumina HumanOmniEx-
pressExome-8 v1.2 BeadChip (http://sciencepark.mdanderson.org/
labs/wood/dna_repair_genes.html for the complete list of genes
involved in different DNA repair pathways), 1457 passed the above
described filters. Among them, 783 were selected after linkage
disequilibrium analysis (R 3.0.3, SNPRelate package, linkage
disequilibrium thresholdX0.8) and analysed for their distribution
among cases and controls and for their potential association with
CBMN frequencies.
Statistical analysis. All the analyses were performed with the open
source R (R 3.1.0). The influence of possible explicative variables
on the frequency of MN, NBUD and NPB was evaluated by
multivariate analysis and/or non-parametric statistical hypothesis
test, since variables did not follow a normal distribution (by
Shapiro–Wilk normality test).
The Wilcoxon rank sum test was applied to compare the
distribution of MN, NBUD and NPB between groups. Correlation
analysis and Kruskal–Wallis rank sum test were also performed to
estimate associations among independent variables (smoking
habits, age, batch effect, etc).
Overall survival was evaluated calculating the time (in months)
between the date of BC diagnosis and the date of death or follow
up termination as the end point for each patient. Event-free
survival was calculated as the time (in months) between the date of
BC diagnosis until date of relapse, death or censorship, whichever
came first. The relative risk of death or of recurrence/progression
against each of the 3 CBMN end points was estimated as hazard
ratios using unadjusted Cox regression (R 3.0.3, Survival package).
MN, NBUD and NPB were all considered continuous or categorical;
multivariate survival analyses were adjusted for matching variables,
risk category and therapy for the whole group of patients. The
prognostic role of CBMN end points on survival was also evaluated
using Kaplan Meier curves and log-rank test. In the best fitted model
survival analyses, hazard ratios were calculated by multivariate Cox
regression, satisfying their proportional hazards (PH) assumptions.
The distribution of genotypes of selected DNA repair variants
among NMIBC cases and controls was evaluated in two steps, first
by w2 Test followed by regression analysis, adjusting for age and
smoking habits.
The genotype influence on the frequency of micronucleated per
1000 binucleated cells was assessed by Kruskal–Wallis rank sum
test only on NMIBC and in the same way as described above and
then confirmed by regression analysis, adjusted for the same match
variables.
Finally, different prediction models were built to evaluate the
diagnostic power of investigated markers: (1) a model including
age and smoking status (model A); (2) model A with the additional
predictor SNPs with different genotype frequencies among cases
and controls (model B); (3) model B with the inclusion of MN
frequencies (model C). Discrimination analysis was conducted
comparing the area under receiver operating characteristic (ROC)
curve of the three nested models by the DeLong’s test (pROC
package).
RESULTS
Study population. The study included PBMC from 158 cases and
158 controls matched by age and smoking habits. For 10 controls
and six cases, technical problems were encountered (i.e., slides
were not scorable or the number of counted binucleated cells was
not sufficient). Since no additional aliquots of cryopreserved
PBMC were available these subjects were excluded from the
analysis. Finally, 152 newly diagnosed, previously untreated males
BC patients and 148 control subjects were included in the study.
The characteristics of the whole cohort are summarised in Table 1.
For 136 patients, tumours were classified as NMIBC (To2),
whereas 16 patients were MIBC (TX2). Forty-one cases had grade
G1 cancer, whereas 64 and 47 had G2 and G3 grade, respectively.
Fifty-four cases were classified as high-risk, 45 as intermediate and
37 as low-risk.
CBMN end points at diagnosis. The 3 CBMN end points
analysed, MN, NBUD and NPB, were not normally distributed
(P¼ 6.10 10e-09, P¼ 3.40 10e-13 and Po2.20 10e-16,
respectively), therefore non-parametric tests were employed to
verify differences among groups. Cytostasis, a biomarker of cell
proliferation and mitogen responsiveness, was assessed by the
nuclear division index via the ratio of mono-, bi- and multi-
nucleated cells as described by Fenech (2007). No differences
among scorers and batches were observed (data not shown).
Overall, cases had a mean MN±standard deviation (s.d.)
frequency of 9.51±4.73 compared with 7.73±3.91 of controls.
The mean NBUD ±s.d. frequency in cases was 5.06±3.36
compared with 3.99±2.44 of controls. MN and NBUD frequencies
were significantly higher in BC cases than in controls (Wilcoxon
rank sum test, P¼ 0.001 and P¼ 0.006, respectively; Table 2,
Figure 1A and B). When stratifying for the type of tumour and
analysing only NMIBC, the differences in MN and NBUD
frequencies among cases and controls were even more significant
(P¼ 0.0005 and P¼ 0.002, respectively; Table 2, Figure 1C and D).
For MIBC the MN frequency trend was similar although results
were not statistically significant. No differences in CBMN end
points were observed after stratification for grade, tumour stage,
risk class or number of recurrences (data not shown).
In a logistic regression model adjusted for age and smoking
similar results were obtained for MN and NBUD frequencies
(Table 3). In particular, for each increase of one unit in the MN
frequency a 1.11 increase of risk of developing BC (all cases vs
controls) and a 1.12 for NMIBC cases were observed. Similar
results were observed when testing NBUD frequencies (1.14 and
1.16 increase of risk, respectively).
MN, NBUD and NPB correlated each other but they did not
correlate with smoking or age (data not shown). A significant
decreased frequency of MN was found in current smokers when
compared with never smokers both when considering all subjects
(adjusted model for age and case-control status, P¼ 0.03) or only
cases (adjusted model for age, P¼ 0.05). BC cases showed higher
MN frequencies in all subgroups with different smoking habits,
though only former smokers showed significant differences in MN
and NBUD levels between cases and controls (P¼ 0.003 and
P¼ 0.009, respectively; Supplementary Figure 1A and B); similarly,
when considering only NMIBCs (for MN in former smokers:
P¼ 0.001; for NBUD in current and former smokers: P¼ 0.04 and
P¼ 0.004, respectively; Supplementary Figure 1C and D). When
smokers were stratified in heavy, moderate and light smokers
according to their consume of cigarettes, the observed trends did
not change. Light smokers had a slight, although not statistically
significant, increase of MN frequency when compared with heavy
smokers or to non-smokers (never and former smokers together;
data not shown but available upon request).
CBMN assay in relation to clinical outcome. The information of
patient follow up is briefly reported in Table 1. Most patients (105)
were treated with either chemotherapy and/or Bacillus Calmette–
Guerin (BCG) therapy. In total, 55 subjects recurred and 24 died.
The mean (median) overall survival and event-free survival for
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patients were 54.5 (50.6) and 41.8 (35.7) months, respectively.
Age and risk classification (Babjuk et al, 2013; Witjes et al, 2014)
were associated with overall survival (but not event-free survival)
in the preliminary univariate assessment of covariates.
No significant associations with survival or recurrence risk were
observed for any of the CBMN end points analysed (data not shown).
Genotype distribution in relation to case-control status and MN
frequencies. A total of 783 SNPs in genes belonging to different
pathways of DNA repair that remained after the quality control
were analysed only in the largest group of NMIBC patients
(n¼ 132) and in controls (n¼ 147). Genotypes frequencies of eight
SNPs were differentially distributed between NMIBC and controls
(Po0.01; w2 test) in a linear model adjusted for age and smoking
habits (Supplementary Table 1). In particular, an increased risk for
NMIBC cases was observed in carriers of the AG or GG genotype
for rs804267 in NEIL2 (P¼ 0.02 and P¼ 0.001, respectively) when
compared with the AA genotype. A similar trend was observed for
carriers of the AC or CC genotypes for NEIL3 rs6817959
(P¼ 0.0006 and P¼ 0.01, respectively) when compared with the
AA genotype. Conversely, having one or two variant alleles for
rs7311151 in RAD52 appeared to be protective when compared
with the reference genotype AA (P¼ 0.004 for the heterozygous
and P¼ 0.03 for the homozygous variant GG). The same
observations were derived for carriers of TC and CC genotypes
for FANCL rs11903456 (P¼ 0.03 for both genotypes when
compared with the wild type).
Ten SNPs were associated with significantly different MN
frequencies according to the genotype stratification in NMIBC
patients (Po0.01; Kruskall–Wallis rank sum test; Supplementary
Table 2). Five of these SNPs were in genes involved in homologous
recombination pathway (Supplementary Figure 2). No differences
in MN frequencies according to a particular genotype were
observed among controls for these 10 SNPs (see Supplementary
Table 2). Interestingly, for RAD51B rs2257127, the MN frequencies
in patients decreased according to the presence of 0, 1 or 2 variant
alleles, whereas in controls this trend was the opposite, though
significant only when comparing the homozygous subjects. Similar
considerations could be done for rs1866074 in TDG, but in this
case MN frequency increased in relation to the number of variant
alleles. Notably, the observed differences were confirmed when
applying an additive model of inheritance of the minor allele (data
not shown). In a linear model controlling for age and smoking
status, NMIBC patients carrying the TC or the CC genotypes of
XPC rs2470458 showed a significant decrease of 2.29 and 4.78 units
of MN, respectively, when compared with the most frequent TT
genotype (P¼ 0.01 and P¼ 0.03). An opposite trend was found for
rs976080 in ERCC8 (increase of 3.31 MN units for CA carriers
when compared with the reference; P¼ 0.002). For rs1866074 in
TDG, there was an increase in the frequencies of MN in carriers of
AG and GG genotypes when compared with carriers of the
reference genotype AA (increase of 2.43 and 4.05 units of MN;
P¼ 0.02 and P¼ 0.001, respectively; Figure 2).
Other SNPs significantly modulating NBUD and NPB frequen-
cies are reported in Supplementary Table 3.
To evaluate the improvement in the performance of NMIBC case
prediction when including genotype of DNA repair genes and MN
frequencies, we analysed three nested models: model A¼ including
age and smoking status; model B¼model Aþ rs804267þ
rs6817959þ rs11903456þ rs7311151; model C¼model BþMN
frequencies. Comparing the area under ROC curve of the three
models there was a statistically significant improvement in
discrimination of NMIBC: in particular the area under ROC
curves were 0.55, 0.75 and 0.79 for model A, B and C, respectively
(model A vs model B: DeLong’s P¼ 2.80 10e-06; model B vs
model C: DeLong’s P¼ 0.02; Figure 3).
DISCUSSION
In the present study, the main result was an increased frequency
of MN and NBUD in cryopreserved lymphocytes of BC cases
assessed at diagnosis compared with controls, either considering all
cases or, with an even more marked difference, the subgroup of
NMIBC.
Table 1. Baseline characteristics of the BC patients and
information at follow up
Covariates Cases (%) Controls (%)
N 152 148
NMIBC 136 (89.5) –
MIBC 16 (10.5) –
Age (years)
Mean±s.d. 62.3±7.9 62.8±8.7
Range 40.0–74.1 40.3–74.9
Smoking Status
Never 21 (13.8) 24 (16.2)
Former 94 (61.8) 90 (60.8)
Current 37 (24.4) 34 (23.0)
T stagea
Ta 84 (55.3) –
T1 46 (30.3) –
T2 14 (9.2) –
T3 1 (0.7) –
T4 1 (0.7) –
Tis 3 (1.9) –
Tx 3 (1.9) –
Grading (1973)a
G1 41 (27.0) –
G2 64 (42.1) –
G3 47 (30.9) –
Grading (2004)a
Non-high grade 77 (50.7) –
High grade 75 (49.3) –
Riska
Low-risk 37 (24.4) –
Intermediate Risk 45 (29.6) –
High-risk 54 (35.5) –
Muscle invasive 16 (10.5)
Recurrence
No 97 (63.8) –
Yes 55 (36.2) –
Number of recurrences
1 35 (63.6) –
2 15 (27.3) –
X3 5 (9.1) –
Progression
No 146 (96.1) –
Yes 6 (3.9) –
Therapy
No 47 (30.9) –
Yes 105 (69.1) –
Cystectomy
No 125 (82.2) –
Yes 27 (17.8) –
BC patient DiacriticalGrave status at
follow up
Alive 128 (84.2) –
Died 24 (15.8)
Of which for BC 11 –
Abbreviations: BC¼bladder cancer; MIBC¼muscle-invasive bladder cancer; NMIBC¼
non-muscle invasive bladder cancer.
aFor reference see: (1) Babjuk et al, 2013; (2) Cheng et al, 2000; (3) Montironi and Lopez-
Beltran, 2005.
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Several studies report an increased baseline frequency of MN
and other CBMN end points in PBMC of cancer patients (reviewed
by Bonassi et al, 2011), confirming the presence of a high genetic
instability in cancer. The majority of studies reported the presence
of increased MN frequencies in individuals with cancer or with pre-
neoplastic lesions. The number of studies performed on PBMC is
quite high (8 studies on breast, 6 on lung, 2 on gastroenteric cancers
and 13 on other malignancies). However, all these studies were mostly
based on a small sample size. The only exceptions are represented by
the study of Duffaud et al (1999), performed on PBMC from 197
controls and 57 head-and-neck cancer patients, and the one of El-
Zein et al (2006), on lymphocytes from 139 lung cancer cases and 130
controls. Thus, our study is the largest study so far on BC patients.
The CBMN assay measures chromosomal DNA damage,
cytostasis and cytotoxicity events in the cell population (Fenech,
2007). It is generally accepted that events of genetic damage such as
MN and NBUD may represent a reflection of misrepaired DNA
breaks, dysregulation on telomere length as well as malfunctions in
the mitotic machinery and DNA amplification (Fenech et al,
2011b). An increase in MN frequency may be considered a
biomarker of chromosome loss and/or breakage, whereas other
anomalies such as NBUD are biomarkers of gene amplification
and/or removal of unresolved DNA repair complexes (Bonassi
et al, 2011). In cancer, an increase of various manifestations of
chromosomal instability is often observed. Assuming that the
induction of chromosomal damage employs similar mechanisms in
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Figure 1. Box plot for comparison of MN and NBUD frequencies in different study groups: MN frequencies in (A) BC cases vs controls and
(C) in NMIBC cases vs controls; NBUD frequencies in (B) BC cases vs controls and (D) in NMIBC cases vs controls.
Table 2. Frequencies of analysed end points by the CBMN assay in peripheral blood mononuclear cells of BC cases and healthy
controls
Controls All BC Cases Pb NMIBC Pb MIBC Pb
Frequenciesa N 148 152 136 16
MN Mean±s.d. 7.73±3.91 9.51±4.73 0.001 9.68±4.77 0.0005 8.06±4.24 0.91
NPB Mean±s.d. 0.88±0.90 0.98±1.03 0.61 0.99±1.03 0.55 0.88±1.09 0.85
NBUD Mean±s.d. 3.99±2.44 5.06±3.36 0.006 5.20±3.41 0.002 3.87±2.69 0.65
Abbreviations: BC¼bladder cancer; MIBC¼muscle-invasive bladder cancer; MN¼micronuclei; NBUD¼nuclear buds; NMIBC¼ non-muscle invasive bladder cancer; NPB¼ nucleoplasmic
bridge. Significant results in bold.
aMean frequencies for 1000 binucleated cells.
bWilcoxon Rank sum test.
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different tissues, the levels of damage measured in lymphocytes
and other surrogate tissues may reflect those present in the cancer-
prone tissues (Bonassi et al, 2011; Slyskova et al, 2012a).
Constitutive DNA damage in cells can be considered a
predictive biomarker indicating a potential increase in cancer risk.
The thresholds of tolerable DNA/chromosomal damage are known
for small eukaryotic organisms such as Saccharomyces cerevisiae,
but little is known for human cells (Khanna, 2015). An increase in
MN frequency in PBMC of BC cases when compared with controls
could be interpreted as an altered status in the DNA damage repair
system or reflects an unknown past exposure. These lead to the
accumulation of chromosomal damage promoting malignant
transformation. However, there is no common agreement on that
and an altered DNA repair system could be also a direct effect in
the organism of the presence of the tumour (Vafa et al, 2002).
A better understanding of the level of systemic DNA damage in
cancer patients may help in a more precise use of therapeutic
intervention. For example, a better definition for the minimum
threshold of DNA/chromosomal damage that kills tumour cells
directly or reactivates mechanisms of tumour-suppression can help
in choosing a more effective chemo- or radiotherapy dosage
(Khanna, 2015).
Several factors may modulate the MN formation and frequency.
Lifestyle habits (smoking, alcohol, vitamin intake) and host factors
(age, gender) are among them, as well as genetic polymorphisms
and exposure to specific mutagen agents (Luzhna et al, 2013).
Notably, we observed a significant decrease in MN frequency in
current smokers when compared with non-smokers (both
considering all subjects and only cases). This is in line with
previous investigations on the impact of smoking on MN levels, in
which the MN rates are higher in non-smokers than in smokers
(reviewed by Nersesyan et al (2014)). The reduction of MN levels
in smokers reported in literature is usually present only in light and
moderate smokers, whereas heavy smokers have higher levels of
MN when also occupational exposure is taken into account
(Bonassi et al, 2003). In our study we did not observe this
phenomenon after categorisation according to the consume of
cigarettes. This is probably due to the fact that the number of
Table 3. Logistic regression model of analysed end points by
the CBMN assay for: (A) BC vs controls; (B) NMIBC vs
controls; (C) MIBC vs controls
Coefficients s.e. P a
MN
BC vs controls 0.104 0.029 o0.01
NMIBC vs controls 0.114 0.030 o0.01
MIBC vs controls 0.011 0.069 0.87
NPB
BC vs controls 0.115 0.121 0.34
NMIBC vs controls 0.130 0.125 0.30
MIBC vs controls  0.016 0.292 0.96
NBUD
BC vs controls 0.132 0.043 o0.01
NMIBC vs controls 0.148 0.045 o0.01
MIBC vs controls  0.037 0.112 0.74
Abbreviations: BC¼bladder cancer; MIBC¼muscle-invasive bladder cancer; MN¼micronuclei
frequencies; NBUD¼ nuclear buds frequencies; NMIBC¼Non-muscle invasive bladder cancer;
NPB¼ nucleoplasmic bridge frequencies; s.e.¼ standard error. Significant results in bold.
aAdjusted for age and smoking.
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Figure 2. MN frequencies in NMIBC patients (n¼ 132) according to genotype distribution of selected SNPs in DNA repair genes (Kruskal–Wallis
Po0.01).
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smokers is too small to observe an effect of smoke on MN
frequencies as reported in other studies. Interestingly, smoking or
formerly smoking BC patients had still higher levels of chromo-
somal damage than controls and the observed effect of smoking
could be due to a constitutively activated antioxidant response
system or an active DNA repair. The question on the effect of
smoking on MN frequencies is still open and results in literature
are controversial (Nersesyan et al, 2014).
Knowing a patient’s basal genetic background and consequently
the individual DNA repair capacity is important for predicting BC
risk. Genetic variants in DNA repair genes that could modify BC
risk and prognosis has already been identified in various studies,
including polymorphisms in XRCC1, XRCC4, XPF, XPD and XPC
(Wang et al, 2010; He et al, 2013; Peng et al, 2014). Among the
eight SNPs significantly associated with NMIBC risk in the present
study, NEIL2 rs804267 has been associated in another study with
risk of recurrence/progression in 421 NMIBC patients, particularly
in those receiving BCG therapy (Wei et al, 2012). Conversely,
rs25487 in XRCC1 was associated with decreased risk of BC in the
present study and in a previous one performed on 227 Chinese BC
patients and 260 controls (Zhu et al, 2016). The functional
significance of XPC rs2470458 is still unclear. XPC rs2470458 has
been indicated as an important and independent predictor for
survival of melanoma patients (Li et al, 2013). In a previous study,
the presence of the variant allele of rs2228000 (in linkage
disequilibrium with rs2470458), which causes a Val499Ala amino
acid change, modulated expression levels of XPC, XPB and XPD
genes in colorectal cancer patients (Slyskova et al, 2012b).
In particular, rs2228000 is well-known to contribute to the
susceptibility to BC in Caucasian populations (Wang et al, 2014).
Finally, BC patients carrying the GG genotype of rs1866074
resulted at decreased risk of disease progression (Wei et al, 2012).
Although the effect of a single SNP on BC risk may be limited, the
combined effect of several SNPs in the same or different genes
could be more significant. Interestingly, tagging SNPs selected
across the entire coding and putative regulatory regions of ERCC8
(known as CSA) were associated with mutagen sensitivity induced
by BPDE in 276 cancer-free smokers as measured with the comet
assay (Leng et al, 2008).
In a review by Fenech and collaborators, a detailed nutrient-
gene interaction model involving various molecular mechanisms
has been reported. In this model, the interaction between a specific
polymorphism in MTHFR, folate and riboflavin deficiency in the
diet lead to MN, NPB and NBUD formation as a consequence of
derived chromosomal instability through several molecular
mechanisms. Analogous models could be plausibly extended to
other pathways such as DNA repair (Fenech et al, 2011b).
MN formation derives from genetic defects in cell cycle
checkpoints and/or DNA repair genes, therefore, genetic variations
in such genes may also affect the levels of chromosome damage by
ultimately modulating the individual DNA repair activity
(Iarmarcovai et al, 2008). Specific genotypes of polymorphisms
in DNA repair genes such as XPD, XRCC1 and XRCC3 were
previously associated with increased MN frequencies in workers
exposed to ionising radiation (Angelini et al, 2005). In the present
study, we evaluated MN frequencies in NMIBC cases in relation to
a large number of polymorphisms in DNA repair genes,
investigated at GWAS level. Among the 10 SNPs associated with
different MN frequencies according to the genotype stratification,
three of them (rs2470458 in XPC, rs1866074 in TDG and rs976080
in ERCC8) resulted in significant associations also in the linear
model. For the polymorphism in XPC a decrease in the MN
frequency was observed in variant allele carriers when compared
with the reference genotypes. For TDG rs1866074, there was an
increase in the frequencies of MN in carriers of AG and GG
genotypes when compared with carriers of the reference genotype
AA. A similar observation was done for carriers of the CA
genotype in ERCC8 rs976080, although in the present study there
were no AA homozygotes. It seems that the presence of a single A
allele for this SNP is sufficient to have a significant increase in the
MN frequency. Interestingly, among the 10 SNPs altering MN
frequency in NMIBC there was an overrepresentation of
polymorphisms in genes involved in the homologous recombina-
tion pathway (5 out of 10; XRCC3 rs861539, SHFM1 rs12704871,
RAD51B rs2257127, PARP1 rs3754376 and rs1136410), which is
supposed to be the main DNA repair pathway involved in the
control of chromosome stability (Serra et al, 2013), and whose
subtle inter-individual differences may be connected to altered MN
frequencies.
We are aware of some weaknesses of the present study. The
CBMN assay is a highly sensitive method to evaluate the action of
genotoxic agents, which may trigger the cascade of events leading
to BC onset. However, in a cross-sectional study like the present
one, this test does not provide any insight as to whether the
observed chromosomal damage is a cause or a consequence of
some exposure/presence of the disease. Moreover, human
lymphocytes are usually used for measuring genotoxic effects
induced by various mutagens in human biomonitoring studies, but
the sensitivity of MN end points may be limited by the repair of
DNA damage during PHA-stimulated lymphocytes culture. On the
other hand, previous studies have demonstrated that there are no
differences in DNA damage and repair capacity between
unstimulated and PHA-stimulated lymphocytes even after 72 h of
culture (Bausinger and Speit, 2015).
A recent review reported all the studies applying the MN assay
in urine-derived cells (UDC) as a diagnostic tool for BC detection
and prognosis (Nersesyan et al, 2014). To our knowledge, only few
studies investigated if the MN assay could be applied as a
diagnostic tool to identify individuals who have BC (Arora et al,
2010; Sharma et al, 2012; de Castro Marcondes et al, 2014). The
currently available data suggested that MN assays in UDC may be
potentially a suitable diagnostic tool for detection of BC and for the
surveillance of the patients (Nersesyan et al, 2014). The specificity
and sensitivity of the assay on UDC has to be further validated in
large studies. The available studies, in fact, are restricted to a small
number of subjects (o50 subjects) highlighting that for large
studies it could be difficult to process a large number of fresh urine
samples. Although urine could be potentially a better specimen for
the study of BC risk rather than PBMC, it should be considered
that the MN assay applied to UDC presents still some limitations.
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Figure 3. ROC curve analysis for discrimination of NMIBC. Model A
investigated the risk reached by adding age and smoking habit; model B
included also the SNPs differentially distributed among cases and controls
(model Aþ rs804267þ rs6817959þ rs11903456þ rs7311151); model C
included model B and MN frequencies.
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UDC extraction needs in fact to be performed on fresh urine to
ensure viable cells. Moreover, the proportion of live cells extracted
from urine is very low so sometimes it is not possible to score
enough cells.
In theory, employing fresh blood is more advantageous from the
practical point of view, since with small blood amounts it is
possible to obtain good cells proliferation after mitogen stimula-
tion. However, there are some drawbacks that limit its use in
human cytogenetic studies. It is in fact quite difficult to process
hundreds of samples in a short time as requested in large studies.
Moreover, it has been demonstrated that to arrange the blood
collection over a long-time interval may increase the experimental
variability due to seasonal variation (Zijno et al, 2007). These
limitations can potentially be overcome by employing cryopre-
served cells. The use of these cells may allow a better study
planning with a priori selection of subjects of interest and the
possibility to data recovery in case of lost samples. Cryopreserved
PBMC have been successfully used before for measuring endogenous
DNA damage and/or DNA repair capacity by different assays
(D’Errico et al, 1999; Chang et al, 2006), but also for MN analysis
with cytokinesis-block (Zijno et al, 2007) bringing significant
advantages in biomonitoring and for biomarkers research.
In conclusion, the observed increase in MN and NBUD
frequencies in BC cases could be used to better estimate individual
BC risk, including in the same model classical risk factors and
DNA repair genetic susceptibility variants. Understanding the level
of systemic chromosomal damage in cancer patients may also help
in more precise therapeutic intervention.
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